David Kylhammar (Former)
11 – 20 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2017
-
Mark
The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Modulators of hypoxic pulmonary vasoconstriction and pulmonary hypertension. Implications for new treatment strategies.
2016)(
- Thesis › Doctoral thesis (compilation)
- 2014
-
Mark
Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
P2Y1 and P2Y12 receptors in hypoxia- and adenosine diphosphate-induced pulmonary vasoconstriction in vivo in the pig.
(
- Contribution to journal › Article
- 2012
-
Mark
Cyclooxygenase-2 inhibition and thromboxane A (2) receptor antagonism attenuate hypoxic pulmonary vasoconstriction in a porcine model.
(
- Contribution to journal › Article
-
Mark
Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia induced pulmonary vasoconstriction in a porcine model.
(
- Contribution to journal › Article
-
Mark
sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model.
(
- Contribution to journal › Article
-
Mark
Levosimendan attenuates hypoxia-induced pulmonary hypertension in a porcine model.
(
- Contribution to journal › Article
- 2010
-
Mark
The sGC stimulator BAY 41-8543 totally reverse hypoxia induced pulmonary hypertension
(
- Contribution to journal › Published meeting abstract
-
Mark
The thromboxane A2 receptor antagonist Daltroban counteracts acute hypoxic pulmonary vasoconstriction
(
- Contribution to journal › Published meeting abstract
- « previous
- 1
- 2
- next »